Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Novartis | INDUSTRY |
| General and Teaching Hospital Celje | OTHER |
| University Medical Centre Ljubljana | OTHER |
| University Medical Centre Maribor |
Not provided
Not provided
Not provided
Not provided
Not provided
The study proposal focuses on multiple sclerosis (MS), a chronic incurable disease of the central nervous system (CNS). The MS disease is characterised by recurrent transient disability progression, quantified by increase in the extended disability status score (EDSS), and subsequent remission (disappearance of symptoms and reduced EDSS score) or, alternatively, a gradual EDSS disability progression and exacerbation of associated symptoms. At the same time, the MS is characterised by multifocal inflammatory lesions disseminated throughout the white and grey matter of the CNS, which can be observed and quantified in the magnetic resonance (MR) scans. The proposed study will address the critical unmet need of computer-assisted extraction and assessment of prognostic factors based from an individual patient's brain MR scan, such as lesion count, volume, whole-brain and regional brain atrophy, and atrophied lesion volume, in order to evaluate the capability for personalized future disability progression prediction.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Atrophied lesion volume derived from MRI predicts confirmed EDSS disability progression | Patients will be divided into two groups based on the presence or absence of EDSS disability progression (DP) during the observation period. The DP converters will be classified as patients with an EDSS change of at least 1.5 if the baseline EDSS is less than 1.0, those with an EDSS change of at least 1.0 if the baseline EDSS is 1.0-5.5, and those with an EDSS change of at least 0.5 if the baseline EDSS is 5.5 or higher [15]. DP converters should have confirmed progression of EDSS impairment over a period of at least 6 months. DP non-converters include individuals who do not meet the criteria for conversion. Atrophied lesion volume will be quantified from MR scans taken >6 months prior to the observed EDSS increase. Advanced artificial intelligence based image analysis tools will be applied to assess the atrophied lesion volume. | Atrophied lesion volume quantified from two or more MR scans across the span of at least one and up to five years |
| Measure | Description | Time Frame |
|---|---|---|
| Atrophied lesion volume derived from MRI predicts conversion to secondary progressive multiple sclerosis | Patients will be divided into two groups, i.e. those who transitioned from clinically isolate syndrome (CIS) or relapsing-remitting (RR) to secondary progressive (SP) form of MS and those who were diagnosed with CIS/RRMS during the observation period. A consilium for patients with MS will confirm the SPMS diagnosis by consensus. Atrophied lesion volume will be quantified from MR scans taken >6 months prior to the observed conversion to the SPMS. Advanced artificial intelligence based image analysis tools will be applied to assess the atrophied lesion volume. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
The study will be based on a retrospective secondary analysis of demographic and clinical data and MRI scans of approximately 1200 Slovenian patients with MS that are regularly monitored between 2015 and present.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ziga Spiclin, PhD | University of Ljubljana | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University medical center Ljubljana | Ljubljana | Osrednjeslovenska | 1000 | Slovenia | ||
| General and teaching hospital Celje |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
Not provided
Not provided
| OTHER |
| Izola General Hospital | OTHER |
Not provided
Not provided
Not provided
| Atrophied lesion volume quantified from two or more MR scans across the span of least one and up to five years |
| Celje |
| 3000 |
| Slovenia |
| General hospital Izola | Izola | Slovenia |
| University medical center Maribor | Maribor | 2000 | Slovenia |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |